Evidence map›Paper›PMID 40164737›Full record

ArticleThe Journal of antibiotics2025

Terramide A: a novel ironophore targeting Acinetobacter baumannii with mechanistic insights into bacterial iron deprivation.

Hanxiang Jiang, Jiangfeng Qi, Jiwen Wang, Jiaqin Chen, Dong Feng, Junbiao Yang, Xinna Liu, Mengqun Liu, Xvzhe Zhou, Zhilong An and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hanxiang Jiang *School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Jiangfeng Qi *School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Jiwen WangSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Jiaqin ChenSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Dong FengNanjing Southern Pharmaceutical Technology Co. Ltd., Nanjing, China.
Junbiao YangSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Xinna LiuSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Mengqun LiuSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Xvzhe ZhouSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Zhilong AnNanjing Southern Pharmaceutical Technology Co. Ltd., Nanjing, China.
Yuanyuan LuSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Chun GeDepartment of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing, China. gechun901020@163.com.
Ying WangSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, China. waying@cpu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acetobacter baumannii poses escalating clinical challenges due to its exceptional adaptability, demanding innovative antimicrobial strategies. This study pioneers an investigation into the antibacterial efficacy and molecular mechanism of Terramide A, a hydroxamate siderophore isolated from Aspergillus terreus, against notorious A. baumannii. Employing a multidisciplinary approach integrating phenotypic characterization with mechanistic interrogation, we demonstrate that Terramide A exerts significant inhibitory effects against A. baumannii and P. aeruginosa, pathogens critically dependent on siderophore-mediated iron acquisition for survival and virulence. Structural characterization underlines the hydroxamate moieties of Terramide A presumably supports its hypothesized role as a fungal siderophore, involving competitive iron sequestration and bacterial homeostasis. Subsequently, multi-omics investigation of susceptible strain AB19606 delineated a metabolic collapse cascade due to iron acquisition competition: (1) impairment of central metabolism and energy production through oxidative phosphorylation (OXPHO) inhibitions; (2) compromised stress adaptation and bacterial flexibility; (3) compensatory overactivation of siderophores biosynthesis and transportation, depleting metabolic intermediates and exacerbating stress; (4) coordinated suppression of virulence determinants, such as secretory systems and biofilm formation. These molecular derangements translated into phenotypic deficits, including quorum sensing, diminished autoinducer peptides production, and morphological/functional abnormalities. In vivo evaluation in a rat skin wound infection model further demonstrated that Terramide A promotes wound healing and mitigates inflammation, supporting its antibacterial efficacy. These findings establish Terramide A as a promising antibacterial agent and provide critical insights into iron-competitive antimicrobial strategies to exploit micro-nutrient deprivation and metabolic dysfunction. However, further research is needed to optimize the siderophore-based scaffold, clarify its mechanisms, and assess therapeutic potential.

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsHydroxamic AcidsIronSiderophoresAcinetobacter InfectionsAnimalsAspergillusBiofilmsMicrobial Sensitivity TestsPseudomonas aeruginosaRatsVirulenceAnti-Bacterial AgentsHydroxamic AcidsIronSiderophores

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.